Sheldon L. Kaplan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sheldon L. Kaplan has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Emin Sami Arısoy
Kocaeli University
5 shared publications - Ener Cagri Dinleyici
Department of Pediatrics, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey
2 shared publications - Tina Q. Tan
Feinberg School of Medicine, Northwestern University
2 shared publications - Adem Karbuz
Council of Forensic Medicine, Ministry of Justice, Republic of Turkiye, Istanbul, Turkiye
1 shared publication - Antonio Vena
Department of Health Sciences (DISSAL), University of Genoa, 16132 Genoa, Italy
1 shared publication - Ayse Tekin Yilmaz
Division of Pediatric Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Kocaeli University, İzmit 41001, Türkiye
1 shared publication
Latest Publications
- 11 November 2023
- Published by Springer Nature
- p. 681-699
Bordetella Pertussis Infection and Hearing Loss
- 11 November 2023
- Published by Springer Nature
- p. 681-699
Bordetella Pertussis Infection and Hearing Loss
- 11 November 2023
- Published by Springer Nature
- p. 421-441
Pneumococcal Meningitis in Children and Hearing Loss
- 11 November 2023
- Published by Springer Nature
- p. 421-441
Pneumococcal Meningitis in Children and Hearing Loss
- 11 November 2023
- Published by Springer Nature
- p. 443-457
Meningococcal Infections in Children and Hearing Loss
- 11 November 2023
- Published by Springer Nature
- p. 443-457
Meningococcal Infections in Children and Hearing Loss
- 11 November 2023
- Published by Springer Nature
- p. 273-287
Bacterial Meningitis in Children and Hearing Loss
- 11 November 2023
- Published by Springer Nature
- p. 273-287
Bacterial Meningitis in Children and Hearing Loss
- 6 September 2023
- Published by Springer Nature
- p. 317-339
Role of Breastfeeding in the Prevention of Infectious Diseases
- 6 September 2023
- Published by Springer Nature
- p. 317-339
Role of Breastfeeding in the Prevention of Infectious Diseases
- Open Access
- 12 April 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (4) , 742
New Antibiotics for Staphylococcus aureus Infection: An Update from the World Association of Infectious Diseases and Immunological Disorders (WAidid) and the Italian Society of Anti-Infective Therapy (SITA)
Staphylococcus aureus is an extremely virulent pathogen that is capable of quickly evolving and developing antibiotic resistance. To overcome this problem, new antibiotics have been developed. Some of these have been licenced for use in clinical practice, mainly for the treatment of adults with acute skin and soft tissue infections, in addition to both community-acquired pneumonia (CAP) and nosocomial pneumonia (hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia). In this paper, the main characteristics and clinical use of new licenced anti-staphylococcal drugs have been discussed. In vitro studies have demonstrated that some new anti-staphylococcal antibiotics have better antimicrobial activity and, at least in certain cases, more favourable pharmacokinetic properties and higher safety and tolerability than the presently available anti-staphylococcal drugs. This suggests that they may have a potential use in reducing the risk of failure of S. aureus therapy. However, an in-depth analysis of microbiological and clinical studies carried out with these new drugs seems to indicate that further studies need to be conducted before the problem of resistance of S. aureus to the antibiotics available today can be completely solved. Considering the overall available research, the drugs that are active against S. aureus appear to present a great therapeutic opportunity for overcoming resistance to traditional therapy. There are advantages in the pharmacokinetic characteristics of some of these drugs and they have the potential to reduce hospital stays and economic costs associated with their use.
- 12 April 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (4) , 742
Open AccessNew Antibiotics for Staphylococcus aureus Infection: An Update from the World Association of Infectious Diseases and Immunological Disorders (WAidid) and the Italian Society of Anti-Infective Therapy (SITA)
Staphylococcus aureus is an extremely virulent pathogen that is capable of quickly evolving and developing antibiotic resistance. To overcome this problem, new antibiotics have been developed. Some of these have been licenced for use in clinical practice, mainly for the treatment of adults with acute skin and soft tissue infections, in addition to both community-acquired pneumonia (CAP) and nosocomial pneumonia (hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia). In this paper, the main characteristics and clinical use of new licenced anti-staphylococcal drugs have been discussed. In vitro studies have demonstrated that some new anti-staphylococcal antibiotics have better antimicrobial activity and, at least in certain cases, more favourable pharmacokinetic properties and higher safety and tolerability than the presently available anti-staphylococcal drugs. This suggests that they may have a potential use in reducing the risk of failure of S. aureus therapy. However, an in-depth analysis of microbiological and clinical studies carried out with these new drugs seems to indicate that further studies need to be conducted before the problem of resistance of S. aureus to the antibiotics available today can be completely solved. Considering the overall available research, the drugs that are active against S. aureus appear to present a great therapeutic opportunity for overcoming resistance to traditional therapy. There are advantages in the pharmacokinetic characteristics of some of these drugs and they have the potential to reduce hospital stays and economic costs associated with their use.